zanidatamab + capecitabine

**Zanidatamab + capecitabine** is a combination therapy used in the treatment of HER2-expressing cancers, particularly advanced or metastatic gastroesophageal adenocarcinoma. **Zanidatamab** is a bispecific monoclonal antibody targeting two distinct epitopes on the HER2 receptor, thereby enhancing HER2 inhibition compared to conventional monoclonal antibodies. **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), a cytotoxic chemotherapy agent that interferes with DNA synthesis by inhibiting thymidylate synthase. The combination offers a dual approach: targeted anti-HER2 activity to block growth signaling, and direct cytotoxicity to inhibit cell proliferation. This therapy has demonstrated promising objective response rates and manageable safety profiles in clinical trials for patients with previously treated or first-line HER2-positive advanced gastroesophageal cancers[3][5][7].

Other names

zanidatamab + capecitabine